Published Date : May 05, 2016
Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro to eliminate the genetic condition. Preimplantation genetic diagnosis is done in cases where there exists a considerably high risk of passing a serious condition or disorder of the parents to their offspring.
According to a report published by a market intelligent company, Transparency Market Research, the Asia Preimplantation genetic diagnosis (PGD) market which was worth US$ 16.0 Mn in 2014, is expected to expand at a CAGR of 6.8% from 2015 to 2023 and reach US$ 28.8 Mn by 2023.
Growing Demand for Healthy Babies Boosts Preimplantation Genetic Diagnosis Market
Preimplantation genetic diagnosis helps in the detection several diseases such as sex-linked disorders, genetic disorders, and chromosomal abnormalities in the embryo. Growing awareness about IVF is also boosting the market. Growing incidence of infertility is driving the preimplantation genetic diagnosis market. The growing wish for a healthy child is driving the preimplantation genetic diagnosis market. The number of people suffering from genetic disorders is increasing at a fast pace and thus, preimplantation genetic diagnosis is increasingly considered for detecting genetic abnormalities.
Aneuploidy Screening Segment Accounted for the Largest Share of the Preimplantation Genetic Diagnosis Market in 2014
The preimplantation genetic diagnosis market is segmented on the basis of end user, test type, and geography. On the basis of type, the market is segmented into aneuploidy screening, gender selection, chromosomal aberrations, HLA typing, X-linked diseases, and single gene disorder. Out of these, the aneuploidy screening segment accounted for the largest share of 35% of the preimplantation genetic diagnosis market in Asia. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality.